12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Chiesi, Cornerstone Therapeutics sales and marketing update

Chiesi granted Cornerstone U.S. rights to market Bethkis tobramycin inhalation solution. The inhaled tobramycin solution was approved last month...

Read the full 82 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >